🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

247 results for “Pari Pharma GmbH” Clear

  1. Sucrose octaacetate [NF], SODIUM CHLORIDE, METHYLPREDNISOLONE VIATRIS 1 g, poudre pour solution injectable (I.V.), LIQUID PREDNISONE

    Pari Pharma GmbH

    IDIOPATHIC PULMONARY FIBROSIS

    phase 2 small molecule active

    1 trial

  2. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  3. Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis

    Pari Pharma GmbH

    Amyotrophic lateral Sclerosis

    phase 2 other active

    1 trial

  4. Trecondi 1 g powder for solution for infusion, FLUDARABINE PHOSPHATE, THIOTEPA, Trecondi 5 g powder for solution for infusion

    Pari Pharma GmbH

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  6. volrustomig, Monalizumab

    Pari Pharma GmbH

    cancerology

    phase 2 small molecule active

    1 trial

  7. A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants with Advanced Rod Cone Dystrophy

    Pari Pharma GmbH

    End-stage rod-cone dystrophy

    phase 1 other active

    1 trial

  8. CITY

    Pari Pharma GmbH

    Cutaneous T-cell lymphomas (CTCL)

    phase 1 other active

    1 trial

  9. Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  10. HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies

    Pari Pharma GmbH

    hematologic malignancies ; acute myeloid leukemias

    phase 1 other active

    1 trial

  11. In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial (BLITZ)

    Pari Pharma GmbH

    Cardiology and vascular disease

    phase 1 other active

    1 trial

  12. MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension

    Pari Pharma GmbH

    Familial Hemophagocytic Lymphohistiocytosis (FHL)

    phase 1 small molecule active

    1 trial

  13. SECRET-HF: Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

    Pari Pharma GmbH

    Non-ischemic Dilated Cardiomyopathies

    phase 1 other active

    1 trial

  14. Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  15. -, -, SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Pari Pharma GmbH

    Pyelonephritis, Kidney Transplant recipients

    approved small molecule active

    1 trial

  16. AMOXICILLIN

    Pari Pharma GmbH

    Adults diagnosed with lower limbs erysipelas

    approved small molecule active

    1 trial

  17. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  18. AMPICILLIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , OFLOXACIN , MOXIFLOXACIN , AZITHROMYCIN , LEVOFLOXACIN , AMOXICILLIN , PRISTINAMYCIN , ERYTHROMYCIN , CIPROFLOXACIN , CLARITHROMYCIN

    Pari Pharma GmbH

    Community acquired pneumonia (CAP)

    approved small molecule active

    1 trial

  19. BILINDA GYNIAL 0,03 mg/2 mg Filmtabletten, Selina Gynial 0,03 mg/0,15 mg Filmtabletten

    Pari Pharma GmbH

    Hormonal contraception

    approved small molecule active

    1 trial

  20. CEFAZOLIN

    Pari Pharma GmbH

    Infection prophylaxis

    approved small molecule active

    1 trial

  21. DONEPEZIL, DONEPEZIL

    Pari Pharma GmbH

    Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease

    approved small molecule active

    1 trial

  22. Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Crohn’s disease

    approved small molecule active

    1 trial

  23. MEROPENEM AND VABORBACTAM , LINEZOLID , TEDIZOLID , SULFAMETHOXAZOLE AND TRIMETHOPRIM , -, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , -, DAPTOMYCIN , -, COLISTIN , -, METRONIDAZOLE , AMIKACIN , IMIPENEM, CILASTATIN AND RELEBACTAM

    Pari Pharma GmbH

    Pyogenic liver abscess

    approved small molecule active

    1 trial

  24. MUCODRILL 600 mg SANS SUCRE, comprimé effervescent édulcoré au sucralose, FOLINORAL 25 mg, gélule, VITAMINE B12 GERDA 250 microgrammes, comprimé sécable, Omacor 1000 mg capsules molles

    Pari Pharma GmbH

    Ultra High Risk of psychosis and first episode psychosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources